Mark Litton MBA ’94 has been appointed to the role of president and CEO of Alpine Immune Sciences, a company specializing in immunotherapies to treat cancer as well as autoimmune and inflammatory diseases. Litton joins Alpine from Alder BioPharmaceuticals, where he served as chief business officer and treasurer since co-founding the company in 2004.

29 Oct 2018